Lumos Pharma has been granted a patent for a compressed tablet containing ibutamoren to treat growth hormone deficiency in pediatric patients. The tablet includes specific ingredients and characteristics, such as a diameter of less than 4mm and a hardness of 2.5-6 Kp. GlobalData’s report on Lumos Pharma gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Lumos Pharma, Cancer treatment biomarkers was a key innovation area identified from patents. Lumos Pharma's grant share as of May 2024 was 38%. Grant share is based on the ratio of number of grants to total number of patents.
Pediatric growth hormone deficiency treatment tablet
A recently granted patent (Publication Number: US11969416B1) discloses a compressed tablet formulation comprising roller-compacted drug-containing granules and extragranular excipients. The tablet includes ibutamoren or a pharmaceutically acceptable salt thereof as the primary active ingredient, along with various excipients such as pregelatinized starch, mannitol, croscarmellose sodium, and magnesium stearate/talc. The tablet is designed to be small in size, weighing less than 20 mg and having a diameter of less than 4 mm, with specific hardness and friability characteristics. The formulation also includes disintegrants and lubricants in specific amounts to ensure proper dissolution and stability of the tablet.
Furthermore, the patent claims cover various aspects of the compressed tablet, including the specific composition of the drug-containing granules, the presence of a coating layer with defined characteristics, and the use of ibutamoren mesylate salt as the active ingredient. The patent also extends to pharmaceutical compositions containing multiple compressed tablets, each meeting the specified criteria. The formulation and manufacturing process detailed in the patent aim to provide a stable and effective dosage form of ibutamoren or its salt, ensuring consistent quality and performance.
To know more about GlobalData’s detailed insights on Lumos Pharma, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
